Release date: 28 August 2024
Promoter – Financial Intermediary
LUMICKS TECHNOLOGIES BVLocation
Description
The project will support the Research and Development investments (RDI) of Lumicks into development of next generation cell avidity and dynamic single-molecule instruments, allowing real-time analysis of molecular and cellular mechanisms and interactions. With large applications in fundamental and applied research, the new instruments can speed up and enhance success rates in drug discovery and development.
Objectives
The project supports the continued development, manufacturing scale-up and market access of Cellular Avidity and Dynamic Single Molecule instruments. These tools allow research institutions, biotech and pharma companies to conduct a more efficient rational drug design and development, ultimately giving more reliable in vitro results before entering in vivo models (clinical stage).
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 20 million
Total cost (Approximate amount)
EUR 46 million
Environmental aspects
The project concerns investments in research and development activities carried out by the promoter and its partners in existing facilities without changing their already authorised scope. The related RDI activities do not fall under either Annex I or Annex II of the Environmental Impact Assessment (EIA) Directive 2011/92/EU (amended by Directive 2014/52/EU). Full environmental details will be verified during appraisal.
Procurement
The EIB requires that all project contracts are procured in accordance with the applicable EU procurement legislation.
Status
Signed - 10/10/2024
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).